Collegium Pharmaceutical, Inc. Interest Expense
Collegium Pharmaceutical, Inc. (COLL) reported Interest Expense of $17.34 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-05-09
- Collegium Pharmaceutical, Inc. interest expense for the quarter ending 2024-03-31 was $17.34M, a 19.08% decline year-over-year.
- Collegium Pharmaceutical, Inc. interest expense for the quarter ending 2023-12-31 was $19.28M, a 6.29% decline year-over-year.
- Collegium Pharmaceutical, Inc. interest expense for the quarter ending 2023-09-30 was $20.77M, a 9.04% increase year-over-year.
- Collegium Pharmaceutical, Inc. interest expense for the quarter ending 2023-06-30 was $21.86M, a 23.10% increase year-over-year.
- Collegium Pharmaceutical, Inc. interest expense for fiscal 2023 was $83.34M, a 31.84% increase from fiscal 2022.
- Collegium Pharmaceutical, Inc. interest expense for fiscal 2022 was $63.21M, a 200.81% increase from fiscal 2021.
- Collegium Pharmaceutical, Inc. interest expense for fiscal 2021 was $21.01M, a 27.24% decline from fiscal 2020.
- Collegium Pharmaceutical, Inc. interest expense for fiscal 2020 was $28.88M, a 3077.34% increase from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $17.34M 10-Q · filed 2024-05-09 | $36.62M derived: sum of 2 quarters · filed 2024-05-09 | $57.39M derived: sum of 3 quarters · filed 2024-05-09 | $79.25M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | $19.28M 10-K · filed 2024-02-22 | $40.05M derived: sum of 2 quarters · filed 2024-02-22 | $61.91M derived: sum of 3 quarters · filed 2024-02-22 | $83.34M 10-K · filed 2024-02-22 |
| 2023-09-30 | $20.77M 10-K · filed 2024-02-22 | $42.63M derived: sum of 2 quarters · filed 2024-02-22 | $64.06M 10-Q · filed 2023-11-07 | $84.63M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-06-30 | $21.86M 10-K · filed 2024-02-22 | $43.29M 10-Q · filed 2023-08-03 | $63.87M derived: sum of 3 quarters · filed 2024-05-09 | $82.91M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-03-31 | $21.43M 10-Q · filed 2024-05-09 | $42.00M derived: sum of 2 quarters · filed 2024-05-09 | $61.05M derived: sum of 3 quarters · filed 2024-05-09 | $78.81M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $20.57M 10-K · filed 2024-02-22 | $39.62M derived: sum of 2 quarters · filed 2024-02-22 | $57.38M derived: sum of 3 quarters · filed 2024-02-22 | $63.21M 10-K · filed 2024-02-22 |
| 2022-09-30 | $19.05M 10-K · filed 2024-02-22 | $36.81M derived: sum of 2 quarters · filed 2024-02-22 | $42.64M 10-Q · filed 2023-11-07 | $47.40M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $17.76M 10-K · filed 2024-02-22 | $23.59M 10-Q · filed 2023-08-03 | $28.35M derived: sum of 3 quarters · filed 2024-02-22 | $33.46M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $5.83M 10-K · filed 2024-02-22 | $10.59M derived: sum of 2 quarters · filed 2024-02-22 | $15.70M derived: sum of 3 quarters · filed 2024-02-22 | $21.12M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $4.76M 10-K · filed 2023-02-23 | $9.87M derived: sum of 2 quarters · filed 2023-02-23 | $15.29M derived: sum of 3 quarters · filed 2023-02-23 | $21.01M 10-K · filed 2024-02-22 |
| 2021-09-30 | $5.12M 10-K · filed 2023-02-23 | $10.54M derived: sum of 2 quarters · filed 2023-02-23 | $16.26M 10-Q · filed 2022-11-03 | $23.99M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $5.42M 10-K · filed 2023-02-23 | $11.14M 10-Q · filed 2022-08-04 | $18.88M derived: sum of 3 quarters · filed 2023-02-23 | $26.94M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $5.72M 10-K · filed 2023-02-23 | $13.46M derived: sum of 2 quarters · filed 2023-02-23 | $21.52M derived: sum of 3 quarters · filed 2023-02-23 | $29.78M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $7.74M 10-K · filed 2022-02-24 | $15.80M derived: sum of 2 quarters · filed 2022-02-24 | $24.06M derived: sum of 3 quarters · filed 2022-02-24 | $28.88M 10-K · filed 2023-02-23 |
| 2020-09-30 | $8.06M 10-K · filed 2022-02-24 | $16.32M derived: sum of 2 quarters · filed 2022-02-24 | $21.14M 10-Q · filed 2021-11-04 | $21.36M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $8.26M 10-K · filed 2022-02-24 | $13.08M 10-Q · filed 2021-08-05 | $13.29M derived: sum of 3 quarters · filed 2022-02-24 | $13.52M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $4.82M 10-K · filed 2022-02-24 | $5.03M derived: sum of 2 quarters · filed 2022-02-24 | $5.26M derived: sum of 3 quarters · filed 2022-02-24 | $5.50M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $211.00K 10-K · filed 2021-02-25 | $439.00K derived: sum of 2 quarters · filed 2021-02-25 | $675.00K derived: sum of 3 quarters · filed 2021-02-25 | $909.00K 10-K · filed 2022-02-24 |
| 2019-09-30 | $228.00K 10-K · filed 2021-02-25 | $464.00K derived: sum of 2 quarters · filed 2021-02-25 | $698.00K 10-Q · filed 2020-11-05 | $3.10M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $236.00K 10-K · filed 2021-02-25 | $470.00K 10-Q · filed 2020-08-05 | $2.87M derived: sum of 3 quarters · filed 2021-02-25 | $8.74M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $234.00K 10-K · filed 2021-02-25 | $2.64M derived: sum of 2 quarters · filed 2021-02-25 | $8.51M derived: sum of 3 quarters · filed 2021-02-25 | $14.66M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $2.40M 10-K · filed 2020-02-27 | $8.27M derived: sum of 2 quarters · filed 2020-02-27 | $14.43M derived: sum of 3 quarters · filed 2020-02-27 | $20.13M 10-K · filed 2021-02-25 |
| 2018-09-30 | $5.87M 10-K · filed 2020-02-27 | $12.03M derived: sum of 2 quarters · filed 2020-02-27 | $17.73M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $6.16M 10-K · filed 2020-02-27 | $11.86M 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $5.70M 10-K · filed 2020-02-27 | |||
| 2016-12-31 | -$19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$17.00K derived: sum of 2 quarters · filed 2019-02-27 | $29.00K derived: sum of 3 quarters · filed 2019-02-27 | $94.00K 10-K · filed 2019-02-27 |
| 2016-09-30 | $2.00K 10-Q · filed 2016-11-10 | $48.00K derived: sum of 2 quarters · filed 2016-11-10 | $113.00K 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $46.00K 10-Q · filed 2016-08-11 | $111.00K 10-Q · filed 2016-08-11 | ||
| 2015-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $186.00K derived: sum of 2 quarters · filed 2017-03-10 | $285.00K derived: sum of 3 quarters · filed 2017-03-10 | $439.00K 10-K · filed 2017-03-10 |
| 2015-09-30 | $97.00K 10-Q · filed 2016-11-10 | $196.00K derived: sum of 2 quarters · filed 2016-11-10 | $350.00K 10-Q · filed 2016-11-10 | |
| 2015-06-30 | $99.00K 10-Q · filed 2016-08-11 | $254.00K 10-Q · filed 2016-08-11 | ||
| 2014-12-31 | $252.00K 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |